Biomarin Pharmaceutical Inc (MIL:1BMRN)
€ 70.52 0 (0%) Market Cap: 13.26 Bil Enterprise Value: 13.36 Bil PE Ratio: 70.93 PB Ratio: 2.84 GF Score: 62/100

Biomarin Pharmaceutical Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 09, 2021 / 08:40PM GMT
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good afternoon. I'm -- sorry. Good afternoon. Thanks for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs. We're really pleased to have BioMarin with us today, for which Jean-Jacques Bienaime, Chairman and CEO; and Brian Mueller, CFO, have joined us.

With that, J.J., I'm going to turn it over to you for introductory comments, and then we can jump to questions.

Jean;Jacques Bienaime
BioMarin Pharmaceutical Inc. - Chairman & CEO

Okay. Thank you, Salveen. We appreciate the opportunity to speak with you today. So as you know, BioMarin is a fully integrated global leader in rare disease drug discovery, development, manufacturing, commercialization. Over the last few years, we've built a company designed for significant growth. Our global infrastructure incorporates a strong base business, delivering close to $2 billion of revenues annually, durable and scalable pipeline of innovative products and regulatory capabilities. And we have

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot